JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Recursion Pharmaceuticals Inc

Fechado

SetorSaúde

5.54 -4.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.41

Máximo

5.94

Indicadores-chave

By Trading Economics

Rendimento

-24M

-202M

Vendas

10M

15M

Margem de lucro

-1,373.259

Funcionários

800

EBITDA

-26M

-191M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+7.76% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

419M

2.7B

Abertura anterior

9.69

Fecho anterior

5.54

Sentimento de Notícias

By Acuity

50%

50%

176 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 23:11 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 de ago. de 2025, 22:45 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 de ago. de 2025, 22:39 UTC

Ganhos

Great-West Lifeco Logs Lower 2Q Profit

5 de ago. de 2025, 21:32 UTC

Ganhos

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 de ago. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 de ago. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 de ago. de 2025, 23:19 UTC

Conversa de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 de ago. de 2025, 23:03 UTC

Conversa de Mercado
Ganhos

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 de ago. de 2025, 22:22 UTC

Ganhos

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 de ago. de 2025, 22:21 UTC

Ganhos

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 de ago. de 2025, 22:20 UTC

Ganhos

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 de ago. de 2025, 22:18 UTC

Ganhos

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 de ago. de 2025, 22:15 UTC

Ganhos

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 de ago. de 2025, 21:58 UTC

Ganhos

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 de ago. de 2025, 21:30 UTC

Ganhos

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 de ago. de 2025, 21:26 UTC

Ganhos

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 de ago. de 2025, 21:23 UTC

Ganhos

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 de ago. de 2025, 21:17 UTC

Ganhos

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

7.76% parte superior

Previsão para 12 meses

Média 6.25 USD  7.76%

Máximo 8 USD

Mínimo 4 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.15 / 4.75Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

176 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.